Cardiovascular Division, Electrophysiology Section, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Cardiovascular Division, University of Adelaide, Adelaide, Australia.
JACC Clin Electrophysiol. 2018 Mar;4(3):331-338. doi: 10.1016/j.jacep.2017.11.021. Epub 2018 Mar 19.
This study reports the long-term outcome of patients with bundle branch re-entrant tachycardia (BBRT) who underwent catheter ablation for ventricular tachycardia (VT).
BBRT is an uncommon mechanism of VT. Data on long-term outcomes of patients with BBRT treated with catheter ablation are insufficient.
Between 2005 and 2016, 32 patients had a sustained VT due to a bundle branch re-entrant mechanism. Diagnosis of BBRT was established per standard published criteria.
The mode of presentation was syncope in 17 patients (53%) and palpitations in 15 (47%). BBRT was inducible in all subjects, and successful ablation of the right bundle branch in 19 patients (59%) or the left bundle branch in 13 patients (41%) was performed. During follow-up of 95 ± 36 months, 6 patients (19%) died, 3 of progressive heart failure and 3 of noncardiac causes. Recurrent VT due to BBRT did not occur in any patient. At baseline, 25 patients (78%) had a prolonged HV interval (>55 ms) and 7 (22%) had a normal HV interval (≤55 ms). In patients with a normal HV interval, there was only 1 death (due to malignancy), and no one developed heart block during 90 ± 36 months of follow-up. Ten patients (31%) had normal left ventricular (LV) function (LV ejection fraction ≥50%), and 22 (69%) had depressed LV function (LV ejection fraction <50%). No deaths were recorded in patients with normal LV function (5 with no implantable cardioverter-defibrillator) compared with 6 deaths among patients with depressed LV function (n = 22; p = 0.07).
Radiofrequency ablation of the bundle branch is an effective therapy for treatment of BBRT. Sustained BBRT can be seen in patients with normal LV systolic function and HV interval with excellent long-term outcomes after ablation.
本研究报告了接受导管消融治疗室性心动过速(VT)的束支折返性心动过速(BBRT)患者的长期结果。
BBRT 是一种不常见的 VT 机制。关于接受导管消融治疗的 BBRT 患者的长期结果的数据不足。
在 2005 年至 2016 年期间,有 32 名患者因束支折返机制而出现持续性 VT。BBRT 的诊断依据标准发表的标准确定。
17 名患者(53%)表现为晕厥,15 名患者(47%)表现为心悸。所有患者均可诱发出 BBRT,并对 19 名患者(59%)的右束支或 13 名患者(41%)的左束支进行了成功消融。在 95±36 个月的随访期间,6 名患者(19%)死亡,3 名死于进行性心力衰竭,3 名死于非心脏原因。没有患者因 BBRT 复发 VT。在基线时,25 名患者(78%)HV 间期延长(>55 ms),7 名患者(22%)HV 间期正常(≤55 ms)。HV 间期正常的患者中,仅有 1 例死亡(因恶性肿瘤),90±36 个月的随访中无 1 例发生心脏阻滞。10 名患者(31%)左心室(LV)功能正常(LV 射血分数≥50%),22 名患者(69%)LV 功能降低(LV 射血分数<50%)。LV 功能正常的患者中,无植入式心脏复律除颤器的患者无死亡(5 例),而 LV 功能降低的患者中,死亡 6 例(n=22;p=0.07)。
束支射频消融是治疗 BBRT 的有效方法。消融后 HV 间期正常且左心室收缩功能正常的患者可出现持续性 BBRT,长期预后良好。